Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (107)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  3. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  4. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  5. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  6. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines

    Cancer discovery, Vol. 14, Núm. 11, pp. 2021-2024

  7. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  8. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

    Journal for immunotherapy of cancer, Vol. 12, Núm. 9

  9. NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

    Journal for immunotherapy of cancer, Vol. 12, Núm. 8

  10. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

  11. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

    Archivos de Bronconeumologia, Vol. 60, pp. S67-S76

  12. Radiotherapy protocols for mouse cancer model

    Methods in Cell Biology (Academic Press Inc.), pp. 99-113

  13. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

  14. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  3. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

  4. Druggable Targets in Cytokine Release Syndromes

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322

  5. ENPP1 Immunobiology as a Therapeutic Target

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 12, pp. 2184-2193

  6. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526